Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Alvotech (ALVO)

11.8   -0.16 (-1.34%) 01-27 14:12
Open: 11.8001 Pre. Close: 11.96
High: 11.99 Low: 11.76
Volume: 34,536 Market Cap: 2,934(M)

Technical analysis

as of: 2023-01-27 4:42:26 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 15.18     One year: 17.73
Support: Support1: 9.84    Support2: 7.9
Resistance: Resistance1: 13    Resistance2: 15.18
Pivot: 11.96
Moving Average: MA(5): 11.91     MA(20): 11.47
MA(100): 7.9     MA(250): 0
MACD: MACD(12,26): 0.8     Signal(9): 0.9
Stochastic oscillator: %K(14,3): 61.2     %D(3): 64.1
RSI: RSI(14): 64.9
52-week: High: 13  Low: 5.19
Average Vol(K): 3-Month: 104 (K)  10-Days: 32 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ ALVO ] has closed above bottom band by 39.9%. Bollinger Bands are 20.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 12 - 12.08 12.08 - 12.13
Low: 11.55 - 11.65 11.65 - 11.71
Close: 11.68 - 11.81 11.81 - 11.91

Company Description

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. It also offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an immunology product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an oncology product. The company was founded in 2013 and is headquartered in Reykjavik, Iceland.

Headline News

Sun, 29 Jan 2023
Dawgs lose to Pensacola for 2nd straight night - Roanoke Times

Sun, 29 Jan 2023
AbbVie's global bestseller Humira to face knockoffs this week (NYSE ... - Seeking Alpha

Tue, 24 Jan 2023
Health Care Sector Update for 01/24/2023: DHR, JNJ, ALVO, IBB, XLV - Nasdaq

Tue, 24 Jan 2023
Despite shrinking by US$115m in the past week, Alvotech (NASDAQ:ALVO) shareholders are still up 21% over 1 year - Yahoo Finance

Tue, 24 Jan 2023
Alvotech (ALVO) and Bioventure Announce Approval of AVT02 as ... -

Fri, 20 Jan 2023
Patient Positioning Devices Market Is Booming Worldwide 2023 ... - Digital Journal

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Neutral
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Drug Manufacturers—Specialty & Generic
Shares Out. 0 (M)
Shares Float 0 (M)
% Held by Insiders 7.214e+007 (%)
% Held by Institutions 73.6 (%)
Shares Short 150 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -1.5215e+008
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) -15.5
Operating Margin (%) -208
Return on Assets (ttm) 0
Return on Equity (ttm) 0
Qtrly Rev. Growth 1
Gross Profit (p.s.) 717.07
Sales Per Share 2.34463e+008
EBITDA (p.s.) 9.67805e+007
Qtrly Earnings Growth 0
Operating Cash Flow 0 (M)
Levered Free Cash Flow -285 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow 0

Stock Dividends

Dividend 0
Forward Dividend 201030
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.